Loading organizations...
§ Private Profile · Wuhan, Hubei, China
Develops alternative antibiotic preparations for animals in veterinary medicine using biotech solutions.
Greenon Biotech develops alternative antibiotic preparations for animals using innovative biotech solutions, aiming to mitigate the global challenge of antimicrobial resistance in veterinary medicine. The organization's focus is on exploring novel biological pathways and compounds to create sustainable and effective therapeutic options for animal health, addressing a critical need for new treatments. Their research and development efforts are directed towards reducing reliance on conventional antimicrobial agents across various animal sectors, including livestock and companion animals. Operating within the broader animal health industry, Greenon Biotech seeks to contribute to improved animal welfare and enhanced food safety standards through its scientific advancements. The company's strategic emphasis is on pioneering next-generation solutions that offer a viable alternative to traditional antibiotics in animal care.
Greenon Biotech has raised $28.1M across 2 funding rounds.
Greenon Biotech has raised $28.1M in total across 2 funding rounds.
Greenon Biotech has raised $28.1M across 2 funding rounds. Most recently, it raised $14.2M Pre-Series B in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 22, 2025 | $14.2M Series A Plus | — | — | Announced |
| Jan 23, 2024 | $13.9M Venture Round | CDH Investments | — | Announced |
Greenon Biotech has raised $28.1M in total across 2 funding rounds.
Greenon Biotech's investors include CDH Investments.